NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Authors

Peter Michael Ellis

Juravinski Cancer Centre, Hamilton, ON, Canada

Peter Michael Ellis , Geoffrey Liu , Michael Millward , Francesco Perrone , Frances A. Shepherd , Sophie Sun , Byoung Chul Cho , Alessandro Morabito , Martin R. Stockler , Rafal Wierzbicki , Victor Cohen , Normand Blais , Randeep S. Sangha , Adolfo G. Favaretto , Jin Hyoung Kang , Carolyn F. Wilson , Joseph O'Connell , Keyue Ding , Glenwood D. Goss , Penelope Ann Bradbury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01000025

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8036^)

DOI

10.1200/jco.2014.32.15_suppl.8036

Abstract #

8036^

Poster Bd #

Abstract Disclosures

FEATURED

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Authors

Peter Michael Ellis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

Poster

An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.

Poster

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.

Poster

A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .